Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis

Medicine (United States)

Volumn 96, Issue 23, 2017, Pages

  Wang, Kai ^b   Ju, Qing ^a   Cao, Jing ^a   Tang, Wenze ^c   Zhang, Jian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

idiopathic pulmonary fibrosis; meta analysis; surfactant protein A; surfactant protein D

Indexed keywords

SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; BIOLOGICAL MARKER;

ACUTE DISEASE; ARTICLE; CONFIDENCE INTERVAL; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; HAZARD RATIO; HUMAN; LUNG INFECTION; META ANALYSIS; MORTALITY RISK; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STANDARD MEAN DIFFERENCE; SYSTEMATIC REVIEW; BLOOD; MORTALITY;

BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 85020389188     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007083     Document Type: Article

References (62)

1. Crystal RG, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769-88
2. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795-806
3. Soo E, Adamali H, Edey AJ. Idiopathic pulmonary fibrosis: current and future directions. Clin Radiol 2017
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
5. White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2016; 194: 1242-51
6. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203
7. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-7
8. King TEJr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164: 1025-32
9. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174: 803-9
10. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-8
11. King TEJr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-81
12. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-9
13. Kim DS, Collard HR, King TEJr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-92
14. Hamai K, Iwamoto H, Ishikawa N, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers 2016; 2016: 4759040
15. Nayak A, Dodagatta-Marri E, Tsolaki AG, et al. An Insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front Immunol 2012; 3: 131
16. Carreto-Binaghi LE, Aliouat el M, Taylor ML. Surfactant proteins, SP-A and SP-D, in respiratory fungal infections: their role in the inflammatory response. Respir Res 2016; 17: 66
17. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactantassociated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160: 1843-50
18. El-Deek SE, Makhlouf HA, Saleem TH, et al. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med Princ Pract 2013; 22: 469-74
19. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162: 258-63
20. Nishikiori H, Chiba H, Ariki S, et al. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2014; 14: 196
21. McFadden RG. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154(3 Pt. 1): 825-6
22. Lu WZH, Wei H. The diagnostic significance of KL-6, SP-A, SP-D and MMP-7 in IPF and its relationship with pulmonary function. Acta Univ Med Anhui 2016; 51: 868-72
23. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13
24. Takahashi H, Shiratori M, Kanai A, et al. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology (Carlton, Vic 2006; 11(Suppl.): S51-4
25. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34
26. Greene KE, King TEJr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19: 439-46
27. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-63
28. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5
29. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60
30. Barlo NP, Van Moorsel CH, Ruven HJ, et al. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 155-61
31. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299: L3-7
32. Doubkova M, Karpisek M, Mazoch J, et al. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 224-34
33. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152(6 Pt. 1): 1860-6
34. Honda Y, Kuroki Y, Shijubo N, et al. Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration 1995; 62: 64-9
35. Kakugawa T, Yokota S, Ishimatsu Y, et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones 2013; 18: 581-90
36. Kennedy B, Branagan P, Moloney F, et al. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 228-36
37. Kuroki Y, Tsutahara S, Shijubo N, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993; 147: 723-9
38. Kuwano K, Maeyama T, Inoshima I, et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 2002; 7: 15-21
39. Molleken C, Poschmann G, Bonella F, et al. MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 41-50
40. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 378-81
41. Okamoto T, Fujii M, Furusawa H, et al. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med 2015; 109: 1576-81
42. Okuda R, Matsushima H, Aoshiba K, et al. Soluble intercellular adhesion molecule-1 for stable and acute phases of idiopathic pulmonary fibrosis. SpringerPlus 2015; 4: 657
43. Papaioannou AI, Kostikas K, Manali ED, et al. Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE). PloS One 2016; 11: e0157789
44. Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013; 143: 1422-9
45. Song L, Zhao JJ, Hua D, et al. The expression of serum SP-A in idiopathic pulmonary fibrosis and its clinical value. Chin J Gerontol 2015; 35: 6465-6
46. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61: 105-19
47. Kati C, Alacam H, Duran L, et al. The effectiveness of the serum surfactant protein D (Sp-D) level to indicate lung injury in pulmonary embolism. Clin Lab 2014; 60: 1457-64
48. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-50
49. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-72
50. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002; 3: 3
51. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-8
52. Schlingemann RO, Rietveld FJ, de Waal RM, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab InvestV 62 1990; 690-6
53. Barbas-Filho JV, Ferreira MA, Sesso A, et al. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001; 54: 132-8
54. Izbicki G, Segel MJ, Christensen TG, et al. Time course of bleomycininduced lung fibrosis. Int J Exp Pathol 2002; 83: 111-9
55. Kumar RK, Watkins SG, Lykke AW. Pulmonary responses to bleomycininduced injury: an immunomorphologic and electron microscopic study. Exp Pathol 1985; 28: 33-43
56. Hagimoto N, Kuwano K, Nomoto Y, et al. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997; 16: 91-101
57. Wang R, Zagariya A, Ibarra-Sunga O, et al. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol 1999; 276(5 Pt. 1): L885-9
58. Carre PC, Mortenson RL, King TEJr, et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991; 88: 1802-10
59. Furuie H, Yamasaki H, Suga M, et al. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997; 10: 787-94
60. Pan LH, Ohtani H, Yamauchi K, et al. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996; 46: 91-9
61. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-7
62. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-91